Two tiny injections every eight weeks beat a daily pill for keeping HIV in check — and for millions of young people in Africa, that could mean the chance to feel like everyone else. That's the finding of a new trial led by researchers at UCL (University College London) and published in The Lancet, one of the world's most respected medical journals.
The problem it tackles is real and urgent. About 1.6 million adolescents ages 10 to 19 live with HIV, and nine out of ten of them call Africa home. Yet the young have historically struggled with treatment more than adults. Study leader Sarah Pett says one big reason is the daily ritual itself: taking a pill every day can draw bullying and stigma, a constant reminder that marks a teenager as different.
The LATA (Long-Acting Treatment in Adolescents) trial followed 476 young people ages 12 to 19 at five clinics across Kenya, South Africa, Uganda and Zimbabwe. All had been on tablets for more than a year, had their virus fully suppressed, and had lived with HIV since birth. Half kept taking a daily tablet — the standard of care. Half switched to a long-acting injectable, a newer medicine that delivers two drugs through one shot.
After almost two years (96 weeks), the results were striking. Only two young people on injections — just 1% — saw the virus bounce back, compared with 15 on daily tablets, or 6%. That rebound matters, because a rise in viral load can harm long-term health and, in some cases, allow HIV to spread to partners or children.
What's more, the young people themselves noticed the difference. Nearly all of them — 94% — said the eight-weekly injections were much easier than taking medicine every single day. And the effect was stronger than anything seen in adults. Earlier adult studies only showed injectables were no worse than tablets; this trial shows they can actually work better, at least for teens.
Still, big barriers stand in the way. The injectables cost more than tablets because the drugs are still under patent, and one of them, rilpivirine, must be kept refrigerated through supply and storage. Every eight weeks a skilled nurse has to give the shot, while tablet users may only see a clinic three or six times a year. There's no generic version yet. Today, teens and adults in the U.S. and Europe can get the injectables, but across most of Africa, they simply aren't available.
That gap worries co-author Dr. Deborah Ford. "The lack of availability of injectable treatments in Africa risks increasing inequalities in HIV care," she warns, leaving most people living with HIV cut off from treatments found in wealthy countries — a divide that could widen with newer versions of the medicine.
The trial offers a clear path forward: support making the injections more widely available to the people who need them most, so that a simpler, quieter kind of care can reach the teenagers who have waited too long for it.